Experienced
Leadership

BioCep is led by a collaborative team of highly-experienced life-science industry executives with proven track records in the research, development and commercialization of biotechnology solutions, as well as finance and business development.
Shmuel Cabilly

Shmuel Cabilly

Lead Investor, Acclaimed Israeli Inventor

Shmuel Cabilly, Ph.D., is a leading scientist and acclaimed Israeli inventor in the field of immunology. His patented inventions are used by hundreds of companies worldwide, including Roche’s Genentech, to develop and commercialize more than 500 antibody-based drugs, such as Herceptin, Rituxan, and Avastin. His invention (the ‘Cabilly patent’ is considered one of the most profitable in Israeli science history.

Dr. Cabilly was also the co-founder and chief scientist of Ethrog Ltd. (acquired by Invitrogen and now part of Thermo Fisher), working alongside Uri Yogev. Dr. Cabilly holds a Ph.D in Immunology from the Hebrew University in Jerusalem, Israel.

Uri Yogev

Uri Yogev | CEO & Chairman

C-Level Medical Veteran & Successful Entrepreneur

Uri Yogev has over 27 years of biotech and pharmaceutical experience as a CEO and successfully sold his own company to the global sector leader. Uri served as the CEO and member of the Board of Directors at Efranat, a clinical stage immunotherapy anti-cancer developer.

Prior to joining Efranat, Uri was the founder and CEO of Ethrog Biotechnology, where he obtained an exclusive distribution agreement with Invitrogen Corp. and later led the acquisition of Ethrog by Invitrogen (today part of Thermo Fisher Scientific corporation, NASDAQ: TMO). During his tenure, Uri managed the establishment of a the tailored and unique production facility, while leading the company to double digits $M in revenues with substantial profits. Uri was a member of Invitrogen’s Management Executive Leadership Team.

Uri holds a BSc. in Life Sciences from the Tel Aviv University, Israel and an MBA from Northwestern University, USA and Tel Aviv University, Israel in the Kellogg Recanati program.

Ilana Margalit

Ilana Margalit, PhD | Chief Scientific Officer (CSO)

Highly Experienced Life Science Technology Specialist, Inventor and Developer

Dr. Ilana Margalit brings over 27 years of experience as a successful life science specialist, inventor and developer. Her experience includes leading product development from an idea to worldwide annual sales exceeding double digits $M in revenues.

She was previously the Chief Technology Officer at Smartzyme, a startup company developing an electrochemical glucose sensor, Chief Chemist at Efranat, a clinical-stage immunotherapy anti-cancer drug company and Chief Scientific Officer working alongside Uri Yogev at Ethrog Ltd (now part of Thermo Fisher), developing and manufacturing innovative research tools in the electrophoresis area.

Ilana holds a BSc and MSc in Chemistry and Ph.D. in Biotechnology from Tel Aviv University, and a Post-Doctoral Fellowship in Biochemistry from Bar Ilan University, Israel.

Nurit Eyal

Nurit Eyal, PhD | Business Development Consultant

Senior Life Sciences Executive & Successful Entrepreneur

Dr. Nurit Eyal brings over 28 years of experience in senior management positions in the life science industry.

She is a serial entrepreneur, who has founded a number of startups in different fields. Her experiences include successfully bringing a line of products to market and closing strategic partnerships with global corporates. Nurit has held many leading business development roles for international and Israeli companies in the life sciences field (Invitrogen, Bio-Rad, Schering Plough, Lundbeck) and was formerly the Head of Life Science Investments at Pamot VC and Yozma VC.

Nurit is the Co-Founder and Head of the Israel Brain Gain National Program (IIA) and Head of the National Accelerators Program for the Ministry of Economy. She holds a PhD from the Weizmann Institute of Science, Department of Chemical Immunology, Israel.

BioCep was founded by Dr. Ofer Klein, Director of the Research Division of Ziv Medical Center, and engineer, Mr. Aaron Lamish. The company operated in its first years from Katzrin Technological Incubator in the northern part of Israel. Together, they developed the company’s first generation instrument for separation of rare cells from various clinical sources. BioCep now plans to adapt and leverage the principles of this technology into a second generation instrument for cell therapy applications.